LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

3.32 -8.29

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.32

Max

3.61

Chiffres clés

By Trading Economics

Revenu

-16M

3M

Ventes

-13M

46M

P/E

Moyenne du Secteur

4.59

54.533

BPA

0.1

Marge bénéficiaire

6.464

Employés

172

EBITDA

-14M

4M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+19.28% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

18M

178M

Ouverture précédente

11.61

Clôture précédente

3.32

Sentiment de l'Actualité

By Acuity

26%

74%

71 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2025, 23:25 UTC

Actions en Tendance

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mai 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mai 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Operations in Uruguay

21 mai 2025, 21:01 UTC

Principaux Mouvements du Marché

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mai 2025, 20:51 UTC

Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 mai 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mai 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mai 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mai 2025, 23:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mai 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mai 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mai 2025, 23:28 UTC

Résultats

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mai 2025, 23:27 UTC

Résultats

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mai 2025, 23:23 UTC

Acquisitions, Fusions, Rachats

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mai 2025, 23:22 UTC

Acquisitions, Fusions, Rachats

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mai 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mai 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mai 2025, 21:42 UTC

Actualités
Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mai 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Ops in Uruguay

21 mai 2025, 21:07 UTC

Actualités

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mai 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 mai 2025, 20:59 UTC

Actualités

Walmart to Cut 1,500 Jobs -- WSJ

21 mai 2025, 20:52 UTC

Résultats

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

19.28% hausse

Prévisions sur 12 Mois

Moyen 4.33 USD  19.28%

Haut 7 USD

Bas 2 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

3 ratings

1

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

71 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.